Quanterix Corporation (QTRX)
After hours:
| Previous close | 17.35 |
| Open | 17.42 |
| Bid | 17.29 x 200 |
| Ask | 17.35 x 100 |
| Day's range | 17.00 - 17.62 |
| 52-week range | 14.26 - 29.70 |
| Volume | |
| Avg. volume | 397,150 |
| Market cap | 663.604M |
| Beta (5Y monthly) | 1.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Quanterix Releases Financial Results for the First Quarter of 2024
BILLERICA, Mass., May 07, 2024--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2024.
- Business Wire
Quanterix To Report First Quarter 2024 Financial Results
BILLERICA, Mass., April 29, 2024--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Wednesday, May 8, 2024 at 8:30 a.m. E.T., to discuss its first quarter 2024 financial results.
- Business Wire
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
BILLERICA, Mass., March 21, 2024--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership path for laboratories interested in offering Tau based research and diagnostic testing services. Quanterix has secured over thirty U.S. patents protecting our innovative ultra-sensitive research products and high-definition diagnostics, and we continue to secure additional patent protection, both in
